CN1813687A - Method for preparing tinidazole biological composite membrane - Google Patents
Method for preparing tinidazole biological composite membrane Download PDFInfo
- Publication number
- CN1813687A CN1813687A CN 200510061683 CN200510061683A CN1813687A CN 1813687 A CN1813687 A CN 1813687A CN 200510061683 CN200510061683 CN 200510061683 CN 200510061683 A CN200510061683 A CN 200510061683A CN 1813687 A CN1813687 A CN 1813687A
- Authority
- CN
- China
- Prior art keywords
- tinidazole
- composite membrane
- solution
- chitosan
- biological composite
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- HJLSLZFTEKNLFI-UHFFFAOYSA-N Tinidazole Chemical compound CCS(=O)(=O)CCN1C(C)=NC=C1[N+]([O-])=O HJLSLZFTEKNLFI-UHFFFAOYSA-N 0.000 title claims abstract description 56
- 229960005053 tinidazole Drugs 0.000 title claims abstract description 55
- 239000012528 membrane Substances 0.000 title claims abstract description 31
- 239000002131 composite material Substances 0.000 title claims description 25
- 238000000034 method Methods 0.000 title description 2
- 229920001661 Chitosan Polymers 0.000 claims abstract description 39
- 238000003756 stirring Methods 0.000 claims abstract description 28
- 239000000243 solution Substances 0.000 claims abstract description 24
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims abstract description 18
- 239000000661 sodium alginate Substances 0.000 claims abstract description 18
- 235000010413 sodium alginate Nutrition 0.000 claims abstract description 18
- 229940005550 sodium alginate Drugs 0.000 claims abstract description 18
- 238000002360 preparation method Methods 0.000 claims abstract description 13
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims abstract description 12
- 239000007864 aqueous solution Substances 0.000 claims abstract description 12
- 239000011324 bead Substances 0.000 claims abstract description 12
- 239000011734 sodium Substances 0.000 claims abstract description 12
- 229910052708 sodium Inorganic materials 0.000 claims abstract description 12
- 239000000725 suspension Substances 0.000 claims abstract description 10
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims abstract description 7
- 239000001110 calcium chloride Substances 0.000 claims abstract description 7
- 229910001628 calcium chloride Inorganic materials 0.000 claims abstract description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 38
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 36
- 239000002904 solvent Substances 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 3
- 229960002713 calcium chloride Drugs 0.000 claims 1
- 229940045110 chitosan Drugs 0.000 claims 1
- 238000001035 drying Methods 0.000 abstract 2
- 239000003814 drug Substances 0.000 description 12
- 239000011259 mixed solution Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 6
- 238000013268 sustained release Methods 0.000 description 4
- 239000012730 sustained-release form Substances 0.000 description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000005611 electricity Effects 0.000 description 3
- 210000000214 mouth Anatomy 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 239000001116 FEMA 4028 Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 150000004957 nitroimidazoles Chemical class 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 229920000867 polyelectrolyte Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
The present invention relates to a preparation method of tinidazole biological complex membrane. Said preparation method includes the following steps: slowly adding 0.05-2.0% of sodium alginate solution into mixed aqueous solution of 0.01-2.0% of chitosan solution and 0.05-0.5% of tinidazole solution, the pH value of the described chitosan solution is 4-6, under the condition of stirring according to 150-5000 rpm making reaction for 30-60 min to obtain sodium alginate-chitosan gel beads, making centrifugal treatment, adding calcium chloride aqueous solution, stirring with 5000-10000 rpm and making reaction for 30-120 min, pouring the obtained mixed suspension into culture dish, drying in drying oven so as to obtain the invented tinidazole biological complex membrane.
Description
Technical field
The present invention relates to the Biodegradable high-molecular composite membrane, particularly relate to tinidazole biological composite membrane and preparation method.
Background technology
Tinidazole (Tinidazole, TNZ), chemical name: 1-[2 (ethylsulfonyl)-ethyl]-2-methyl-5-nitro imidazoles.Be the nitroimidazoles medicine of a new generation, the clinical infection that is mainly used in treatment and prevention anaerobism mattress.Compare with metronidazole, its characters function is stronger, onset is faster, distribute in the long half time, body wide, high, the better tolerance of curative effect, and common formulations is mainly based on tablet and infusion solution.But behind the systemic administration, still have comparatively serious digestive system and neural untoward reaction such as nauseating, vomiting, anorexia, stomachache.The patent of Song Cangsang (CN 1279945A) has been set forth tinidazole and stomach floating preparation adjuvant (being made up of carboxymethyl cellulose, hard ester acid, sodium bicarbonate, polyvidon) and has been mixed in proportion and is mixed with capsule, be used for digestion such as gastric ulcer shape treatment of diseases, can reduce every day, each dosage.By changing the pharmaceutical dosage form of tinidazole, place the part that the position of pathological changes is arranged, the untoward reaction that can avoid systemic administration to cause reduces poisonous side effect of medicine and dosage.Continually developed novel form such as membrane, suppository and the stick of the various patient's of being used for topical therapeutics in recent years, obtained the curative effect identical with tablet.The patent of Song Cangsang (CN 1278429A) has disclosed tinidazole behind beta-cyclodextrin inclusion compound agent enclose, forms vagina slowly-releasing suppository with the auxiliary shape agent mixed-forming again, and it is fast that its characteristics blood drug level reaches the peak, and duration of efficacy is long.The patent of Yuan Hui (CN 1559406A) has been invented one group of pharmaceutical preparation, and this pharmaceutical preparation is tinidazole beta-schardinger dextrin-or derivatives thereof clathrate, and gel, medicine membrane of oral cavity, compound recipe gargarism and stick etc. are arranged.In order further to improve curative effect, keep the valid density of local patholoic change position long period, seen at present about the relevant report of oral cavity with slow-release medicine-membrane research.Zhou Yanni (Chinese Hospitals pharmaceutical journal, 1999,19 (6), 368～369) is a principal agent with the tinidazole, and high molecular slow-release material polyvinyl alcohol, sodium carboxymethyl cellulose are carrier, make the matrix type sustained release film formulation, are used for the treatment of periodontitis, gingivitis.Wang Zhichao (Chinese biochemical drug magazine, 2003,24 (3), 144～145) is that filmogen prepares tinidazole chitosan tooth slow-release medicine-membrane with chitosan, carbopol, carboxymethyl cellulose.But slow-releasing system in the past is confined to blend, and medicine is not to be embedded in macromolecular structure inside, can not reach the purpose of sustained release, causes the medicine unnecessary loss, has limited the performance of curative effect simultaneously.Therefore need further improvement and perfect.
Summary of the invention
The object of the invention is to provide a kind of preparation method of tinidazole biological composite membrane.Pharmaceutical pack is embedded in the macromolecule network, improves the embedding rate of medicine, reach the purpose of sustained release tinidazole by regulating preparation condition and sodium alginate and chitosan proportioning.The preparation method of tinidazole biological composite membrane provided by the invention is as follows:
Composition of raw materials is formed: weight percentage % (w/w)
Tinidazole 0.05～0.5
Sodium alginate 0.05～2.0
Chitosan 0.01～2.0
Calcium chloride 0～1.0
Yu Weishui.
Sodium alginate soln with 0.05～2.0% slowly joins in the mixed aqueous solution of 0.01～2.0% chitosan solution and 0.05～0.5% tinidazole solution, the pH value of described chitosan solution is 4～6, after 1500-5000rpm stirs and reacts 30～60min down, obtain the sodium alginate-chitosan gel beads, in the mixture impouring culture dish with gained, it is dry to put into 20～50 ℃ of baking ovens, and skinning gets faint yellow tinidazole biological composite membrane.
The present invention above-mentioned obtain the sodium alginate-chitosan gel beads after, carry out centrifugal treating, add 0＜～1.0% calcium chloride water, after 5000～10000rpm stirs and reacts 30～120min down, in the mixing suspension impouring culture dish with gained, it is dry to put into 20～50 ℃ of baking ovens, obtains tinidazole biological composite membrane of the present invention.
Chitosan solution of the present invention contains 2% acetic acid.
Chitosan solution of the present invention is formulated by 2% acetic acid and acetone 1: 1 by volume.
Tinidazole solution of the present invention is formulated by acetone.
Technique effect of the present invention:
Because sodium alginate that is adopted and chitosan are the macromolecular materials of two kinds of difference bear electricity and positive electricity, carrier material self is charged, if in the tinidazole adding system with positively charged, can with the sodium alginate generation electrostatic interaction of bear electricity, along with sodium alginate and chitosan form polyelectrolyte, the tinidazole pharmaceutical pack is embedded in the macromolecule network, show good medicine carrying character, avoid the medicine unnecessary loss, reach the purpose of sustained release tinidazole medicine simultaneously.Add calcium chloride and can make carrier polymer further crosslinked, the tinidazole embedding rate further improves.
The tinidazole biological composite membrane that the present invention prepares is in pH=4～8 scopes, and it is lower to demonstrate water sucting degree, is suitable for the use of oral cavity partial diseased region and keeps composite membrane intensity constant; The tinidazole embedding rate reaches 30%～96%.The pH value by regulating chitosan aqueous solution or the ratio of sodium alginate and chitosan can be controlled the release of tinidazole.
The specific embodiment
Embodiment 1
Under high speed machine stirs, 1% (w/w) chitosan solution (containing 2% acetic acid) is slowly joined in the mixed solution of 1% (w/w) sodium alginate and 0.5% (w/w) tinidazole (formulated) by acetone, 1500-5000rpm stirs reaction 30～60min down, in the mixture impouring culture dish with gained, it is dry to put into 20～50 ℃ of baking ovens, skinning gets faint yellow tinidazole biological composite membrane.
Embodiment 2
Under high speed machine stirs, in 0.25% (w/w) sodium alginate aqueous solution, slowly add pH and be 4.0 0.25% (w/w) chitosan solution (solvent is formed by the configuration in 1: 1 by volume of 2% acetic acid and acetone) and the mixed solution of 0.5% (w/w) tinidazole acetone soln, stir reaction 30～60min down through 1500-5000rpm, obtain the sodium alginate-chitosan gel beads, centrifugal (rotating speed 3000rpm, 10min), the volumetric soiutions volume adds 0.07%CaCl again
2After 5000～10000rpm stirred and reacts 30～120min down, in the mixing suspension impouring culture dish with gained, it was dry to put into 20～50 ℃ of baking ovens, and skinning gets faint yellow tinidazole biological composite membrane.
Embodiment 3
Under high speed machine stirs, in 0.25% (w/w) sodium alginate aqueous solution, slowly add pH and be 5.0 0.25% (w/w) chitosan solution (solvent is formed by the configuration in 1: 1 by volume of 2% acetic acid and acetone) and the mixed solution of 0.5% (w/w) tinidazole acetone soln, stir reaction 30～60min down through 1500-5000rpm, obtain the sodium alginate-chitosan gel beads, centrifugal (rotating speed 3000rpm, 10min), the volumetric soiutions volume adds 0.07%CaCl again
2Behind vigorous stirring 30～120min, in the mixing suspension impouring culture dish with gained, it is dry to put into 20～50 ℃ of baking ovens again, and skinning gets faint yellow tinidazole biological composite membrane.
Embodiment 4
Under high speed machine stirs, in 0.25% (w/w) sodium alginate aqueous solution, slowly add pH and be 6.0 0.25% (w/w) chitosan solution (solvent is formed by the configuration in 1: 1 by volume of 2% acetic acid and acetone) and the mixed solution of 0.5% (w/w) tinidazole acetone soln, stir reaction 30～60min down through 1500-5000rpm, obtain the sodium alginate-chitosan gel beads, centrifugal (rotating speed 3000rpm, 10min), the volumetric soiutions volume adds 0.07%CaCl again
2Behind vigorous stirring 30～120min, in the mixing suspension impouring culture dish with gained, it is dry to put into 20～50 ℃ of baking ovens again, and skinning gets faint yellow tinidazole biological composite membrane.
Embodiment 5
Under high speed machine stirs, in 0.1% (w/w) sodium alginate aqueous solution, slowly add certain pH and be 6.0 0.25% (w/w) chitosan solution (solvent is formed by the configuration in 1: 1 by volume of 2% acetic acid and acetone) and the mixed solution of 0.5% (w/w) tinidazole acetone soln, stir reaction 30～60min down through 1500-5000rpm, obtain the sodium alginate-chitosan gel beads, centrifugal (rotating speed 3000rpm, 10min), the volumetric soiutions volume adds 0.07%CaCl again
2Behind vigorous stirring 30～120min, in the mixing suspension impouring culture dish with gained, it is dry to put into 20～50 ℃ of baking ovens again, and skinning gets faint yellow tinidazole biological composite membrane.
Embodiment 6
Under high speed machine stirs, in 0.4% (w/w) sodium alginate aqueous solution, slowly add pH and be 6.0 0.25% (w/w) chitosan solution (solvent is formed by the configuration in 1: 1 by volume of 2% acetic acid and acetone) and the mixed solution of 1mL 0.5% (w/v) tinidazole acetone soln, stir reaction 30～60min down through 1500-5000rpm, obtain the sodium alginate-chitosan gel beads, centrifugal (rotating speed 3000rpm, 10min), the volumetric soiutions volume adds 0.07%CaCl again
2Behind vigorous stirring 30～120min, in the mixing suspension impouring culture dish with gained, it is dry to put into 20～50 ℃ of baking ovens again, and skinning gets faint yellow tinidazole biological composite membrane.
Embodiment 7
Under high speed machine stirs, in 0.4% (w/w) sodium alginate aqueous solution, slowly add certain pH and be 6.0 0.1% (w/w) chitosan solution (solvent is formed by the configuration in 1: 1 by volume of 2% acetic acid and acetone) and the mixed solution of 0.5% (w/w) tinidazole acetone soln, stir reaction 30～60min down through 1500-5000rpm, obtain the sodium alginate-chitosan gel beads, centrifugal (rotating speed 3000rpm, 10min), the volumetric soiutions volume adds 0.07%CaCl again
2Behind vigorous stirring 30～120min, in the mixing suspension impouring culture dish with gained, it is dry to put into 20～50 ℃ of baking ovens again, and skinning gets faint yellow tinidazole biological composite membrane.
Embodiment 8
Under high speed machine stirs, in 0.4% (w/w) sodium alginate aqueous solution, slowly add certain pH and be 6.0 0.4% (w/v) chitosan solution (solvent is formed by the configuration in 1: 1 by volume of 2% acetic acid and acetone) and the mixed solution of 0.5% (w/w) tinidazole acetone soln, stir reaction 30～60min down through 1500-5000rpm, obtain the sodium alginate-chitosan gel beads, centrifugal (rotating speed 3000rpm, 10min), the volumetric soiutions volume adds 0.07%CaCl again
2Behind vigorous stirring 30～120min, in the mixing suspension impouring culture dish with gained, it is dry to put into 20～50 ℃ of baking ovens again, and skinning gets faint yellow tinidazole biological composite membrane.
Claims (5)
1, a kind of preparation method of tinidazole biological composite membrane is characterized in that: adopt tinidazole, and sodium alginate, chitosan, calcium chloride, water are raw material, and composition of raw materials is a weight percentage, and wherein the calcium chloride weight percentage is 0～1.0%, the steps include:
Sodium alginate soln with 0.05～2.0% slowly joins in the mixed aqueous solution of 0.01～2.0% chitosan solution and 0.05～0.5% tinidazole solution, the pH value of described chitosan solution is 4～6, after 1500-5000rpm stirs and reacts 30～60min down, obtain the sodium alginate-chitosan gel beads, in the mixture impouring culture dish with gained, it is dry to put into 20～50 ℃ of baking ovens, and skinning gets faint yellow tinidazole biological composite membrane.
2, according to the preparation method of the described tinidazole biological composite membrane of claim 1, it is characterized in that obtaining the sodium alginate-chitosan gel beads, centrifugal back, adding weight percentage are 0＜～1.0% calcium chloride water, after 5000～10000rpm stirs and reacts 30～120min down, the mixing suspension of gained is poured in the culture dish, it is dry to put into 20～50 ℃ of baking ovens of baking oven, obtains tinidazole biological composite membrane of the present invention.
3,, it is characterized in that described chitosan solution contains 2% acetic acid according to the preparation method of the described tinidazole biological composite membrane of claim 1.
4, according to the preparation method of the described tinidazole biological composite membrane of claim 1, it is characterized in that described chitosan solution, solvent is formulated by 2% acetic acid and acetone 1: 1 by volume.
5,, it is characterized in that described tinidazole solution is formulated by acetone according to the preparation method of the described tinidazole biological composite membrane of claim 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510061683 CN1813687A (en) | 2005-11-25 | 2005-11-25 | Method for preparing tinidazole biological composite membrane |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510061683 CN1813687A (en) | 2005-11-25 | 2005-11-25 | Method for preparing tinidazole biological composite membrane |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1813687A true CN1813687A (en) | 2006-08-09 |
Family
ID=36906123
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200510061683 Pending CN1813687A (en) | 2005-11-25 | 2005-11-25 | Method for preparing tinidazole biological composite membrane |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1813687A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102511481A (en) * | 2011-12-14 | 2012-06-27 | 贵州省烟草科学研究所 | Method for embedding metalaxyl |
-
2005
- 2005-11-25 CN CN 200510061683 patent/CN1813687A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102511481A (en) * | 2011-12-14 | 2012-06-27 | 贵州省烟草科学研究所 | Method for embedding metalaxyl |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1222279C (en) | Prolonged release bioadhesive vaginal gel dosage form | |
| EP1802295B1 (en) | Oral pharmaceutical composition for targeted transport of a platinum complex into the colorectal region, method for producing and use as medicament thereof | |
| CN103040727A (en) | Preparation method of drug and protein sustained-release alginate hybrid gel | |
| CN105233325A (en) | Thermosensitive dual-administration nanocomposite hydrogel as well as preparation method and application thereof | |
| CN101984958A (en) | Nanoscale albendazole micropowder and preparation method thereof | |
| CN114524950A (en) | Magnetic targeting hydrophobic drug carrier hydrogel and preparation method and application thereof | |
| CN113476666A (en) | Injectable articular cartilage repair material capable of slowly releasing melatonin for long time, preparation method and application thereof | |
| CN115073769A (en) | Active oxygen response supramolecular hydrogel for promoting tissue regeneration and preparation method thereof | |
| CN102091084B (en) | Compound capsule and preparation method thereof | |
| CN105801870A (en) | Preparation method of polysialic acid-hyaluronic acid composite gel, obtained product and application | |
| CN109106695A (en) | A kind of preparation method of the segmented intestine targeted sustained-release micro-spheres of brufen | |
| Arfin et al. | Alginate: recent progress and technological prospects | |
| CN106421807A (en) | Preparation method of insulin-supporting carboxymethyl chitosan/chitosan nanometer preparation | |
| CN1813687A (en) | Method for preparing tinidazole biological composite membrane | |
| CN102304259B (en) | Preparation method of fibroin blending material with gradually degrading performance | |
| CN115350287A (en) | Nanometer preparation with pH/ROS dual responsiveness, and preparation method and application thereof | |
| CN112426537B (en) | Polypeptide nano micelle and preparation method and application thereof | |
| KR102450652B1 (en) | Use of bio-transformed bear bile powder in preparation of anti-inflammatory drugs | |
| CN109999009B (en) | Oral sustained-release preparation of antitumor drug and preparation method thereof | |
| CN113648296A (en) | Preparation method of ibuprofen transdermal controlled release nano material | |
| WO1997029777A1 (en) | Drug delivery system using galactoxyloglucan | |
| CN108721325A (en) | Smectite turbid liquor and preparation method thereof | |
| CN112245399A (en) | Dihydromyricetin gastric floating pill and preparation method thereof | |
| CN116509795A (en) | Injectable and drug sustained-release hydrogel and preparation method and application thereof | |
| CN114736254B (en) | Natural flavonoid derivative medicine and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |